CoreLab Partners, Inc., announced the opening of an office in Tokyo, Japan under the wholly owned subsidiary of CoreLab Partners Japan, K.K.
“We are pleased to announce the creation of our new subsidiary in Asia corresponding with the opening of an office in central Tokyo” said CoreLab Partners’ President and Chief Executive Officer, Dr. Mike Woehler. “This expanded presence is a natural extension of our geographic reach and global strategy to serve our growing base of multinational biopharma companies operating in the region and will complement our operational capability which was established in Shanghai, China over a decade ago” added Woehler.
CoreLab Partners currently has a business alliance in Japan with Suzuken Co. Ltd. which markets its cardiac safety services; this new presence is designed to further establish the global brand in the Pacific Rim and expand their full line of imaging sciences capabilities in Southeast Asia. “CoreLabs has been present in the region since 1999 and has conducted hundreds of drug development studies in both cardiac safety and imaging for a variety of sponsor partners. The addition of a local Regional Director and Business Development professional will allow CoreLab Partners to better service our client base by nurturing current relationships and opening up new markets for our full line of cardiac safety and imaging services” said Kevin Duffy, Vice President, Global Business Development.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.